***TASK***
the task is to simplify the input abstract of a biomedical literature

***INPUT***
the input is the abstract of a biomedical literature

***OUTPUT***
the output is the simplified abstract for the input abstract of a biomedical literature

***DOCUMENTATION***

***EXAMPLES***

Input: We did not identifiy any new trials for inclusion or exclusion in this 2014 update. One study involving 110 participants (55 participants in each group) met our inclusion criteria. The corticosteroid (prednisolone) showed a benefit in shortening the median time to resolution of headaches (five days in the treatment group versus 13 days in the control group, P value < 0.0001). Corticosteroids were also associated with smaller numbers of participants who still had headaches after a two-week course of treatment (9.1% versus 45.5%, P value < 0.0001). The number of patients who needed repeat lumbar puncture was also smaller in the treatment group (12.7% versus 40%, P value = 0.002). There was a reduction in the median time of analgesic use in participants receiving corticosteroids (10.5 versus 25.0, P value = 0.038). There were no reported adverse effects from prednisolone in the treatment group. Corticosteroids significantly help relieve headache in patients with eosinophilic meningitis, who have a pain score of four or more on a visual analogue scale. However, there is only one RCT supporting this benefit and this trial did not clearly mention allocation concealment and stratification. Therefore, we agreed to grade our included study as a moderate quality trial. Future well-designed RCTs are necessary.
Output:

We conducted a systematic review and meta-analysis of randomised controlled trials of corticosteroids for treating eosinophilic meningitis. The evidence is current to December 2014. We found only one randomised controlled trial that matched our criteria. This trial included 129 patients (63 in the treatment group, prednisolone 60 mg/day, divided into three doses for two weeks and 66 in the control group, placebo). However,19 patients were lost to follow-up. The included study showed that the median time to resolution of headaches was lower in the group treated with prednisolone (10.5 days versus 25 days) and the number of patients who still had headaches after 14 days was lower in the prednisolone group compared to the control (9.1% versus 45.5%). There were statistically significant differences, which favoured the treatment group, in other outcomes including the frequency of acetaminophen (paracetamol) use (median of number of times used) amongst those who still had headaches after 14 days of prednisolone treatment and the mean time until complete disappearance of headache. The number of patients who needed repeat lumbar puncture was also smaller in the treatment group. There were no reported adverse effects from prednisolone in the treatment group. Corticosteroids significantly help relieve headache in patients with eosinophilic meningitis, who have a pain score of four or more on a visual analogue scale. Given the lack of allocation concealment and blinding (especially in a trial with subjective outcomes), and the attrition (loss of participants), we graded our evidence as moderate quality.